동물용 항균 펩타이드 시장 : 제품 유형, 동물 유형, 투여 방법, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Animal Antibacterial Peptide Market is projected to grow by USD 14.68 billion at a CAGR of 17.68% by 2032.

Animal antibacterial peptides, including antimicrobial peptides used in livestock, aquaculture, companion animals, and veterinary biologics research, are gaining strategic relevance as animal health systems respond to antimicrobial resistance, stricter antibiotic stewardship, and rising demand for residue-conscious protein production.

These peptides are short, biologically active molecules that can disrupt microbial membranes, modulate immune responses, and support targeted pathogen control. Their potential value is strongest where conventional antibiotics face regulatory pressure, resistance concerns, or performance limitations. Market interest is supported by global surveillance from the World Health Organization, the World Organisation for Animal Health, and national veterinary agencies, which consistently identify antimicrobial resistance as a One Health risk affecting humans, animals, food systems, and the environment.

Transformative Shifts in the Market Landscape

The landscape for animal antibacterial peptides is being reshaped by antibiotic-reduction policies, precision livestock management, and the shift from therapeutic-only intervention toward preventive animal health. The European Union banned antibiotic growth promoters in 2006, and the United States implemented Veterinary Feed Directive controls to strengthen veterinary oversight of medically important antimicrobials. These policy changes continue to influence global expectations for alternatives.

Commercial development is moving from broad-spectrum substitution to use-case-specific deployment in feed additives, topical veterinary applications, aquaculture disease management, mastitis control research, and companion animal dermatology. Buyers increasingly evaluate efficacy, stability, palatability, delivery format, withdrawal-period implications, and compatibility with probiotics, organic acids, enzymes, vaccines, and biosecurity programs.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating the discovery and optimization of animal antibacterial peptides by enabling high-throughput sequence screening, activity prediction, toxicity modeling, and structure-function analysis. Machine learning models can evaluate peptide charge, hydrophobicity, amphipathicity, molecular weight, and predicted membrane interaction to prioritize candidates before costly wet-lab validation.

AI is also improving formulation and deployment decisions. In animal health, peptide performance depends on species, pathogen load, gut environment, feed processing temperature, delivery route, and microbiome effects. Predictive analytics can help connect farm-level data, veterinary diagnostics, and peptide performance outcomes, supporting more precise use while reducing trial-and-error development cycles.

Key Regional Insights

Asia-Pacific is an important demand center because it combines large livestock populations, aquaculture intensity, and increasing food safety expectations. China, India, Japan, South Korea, Australia, and ASEAN markets are strengthening animal health infrastructure while seeking antibiotic stewardship solutions compatible with high-volume poultry, swine, dairy, and aquaculture production.

North America benefits from advanced veterinary diagnostics, strong animal nutrition capabilities, and established regulatory pathways for veterinary oversight. Latin America, led by Brazil and Mexico, has opportunity tied to poultry, beef, dairy, swine, and export-oriented protein production. Europe remains a regulatory benchmark due to its long-standing restrictions on growth-promoting antibiotics and continued emphasis on antimicrobial reduction, veterinary prescription discipline, and documented responsible use.

The Middle East is developing opportunities through poultry integration, dairy modernization, and food security investment, while Africa presents long-term potential as livestock productivity, veterinary access, cold-chain capacity, and disease prevention programs expand. Across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa, adoption depends on local regulatory classification, cost-in-use, evidence quality, manufacturing consistency, and compatibility with existing animal health programs.

Key Economic Group Insights

ASEAN is a relevant growth cluster because poultry, swine, and aquaculture production are central to regional food security, and producers are increasingly attentive to export market standards, residue management, and disease prevention. The GCC is shaped by food import dependence, intensive poultry and dairy projects, and government-backed food security strategies that favor reliable disease-prevention tools suited to controlled production systems.

The European Union remains highly influential for animal antibacterial peptide commercialization because its antimicrobial stewardship framework often sets reference expectations for safety, efficacy, environmental responsibility, and responsible use. BRICS markets combine scale and production diversity, with China, India, Brazil, Russia, and South Africa representing different demand profiles across feed, veterinary, dairy, poultry, swine, and aquaculture applications.

G7 economies contribute advanced research capacity, regulatory science, veterinary diagnostics, and premium animal health purchasing power. NATO countries overlap significantly with high-income veterinary markets, where biosecurity, supply chain resilience, reduced antimicrobial dependence, and preparedness against transboundary animal diseases are increasingly treated as strategic priorities.

Key Country Insights

The United States is supported by sophisticated veterinary oversight, advanced animal health infrastructure, and strong demand for antibiotic alternatives in poultry, swine, dairy, beef, and companion animal care. Canada aligns with similar stewardship objectives and science-based veterinary regulation, while Mexico's opportunity is linked to integrated poultry, swine, dairy, and export-oriented food production.

Brazil is a major opportunity due to its global role in poultry, beef, and pork exports, while the United Kingdom, Germany, France, Italy, and Spain remain important European markets because of mature veterinary systems, established livestock industries, and pressure to document responsible antimicrobial use. Russia's demand is influenced by domestic animal protein production, food security priorities, and import substitution dynamics.

China and India represent scale-driven opportunities across livestock and aquaculture, although commercialization depends on regulatory clarity, cost competitiveness, and reliable field evidence. Japan, Australia, and South Korea offer quality-focused markets with advanced veterinary standards, strong biosecurity cultures, and interest in science-backed animal health innovation, particularly where antimicrobial stewardship aligns with food safety and animal welfare objectives.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically relevant efficacy data, species-specific validation, and transparent safety profiles. Peptide candidates should be tested against priority veterinary pathogens, evaluated for resistance-development risk, and benchmarked against existing antibiotics, probiotics, organic acids, enzymes, and vaccination programs.

Companies should invest in formulation technologies that improve stability during feed processing, gastrointestinal transit, topical use, injectable formats, or water delivery. Strategic partnerships with veterinary universities, diagnostic laboratories, feed integrators, and contract research organizations can shorten validation timelines and strengthen technical credibility.

A successful commercialization strategy should include regulatory mapping by country, cost-in-use modeling, scalable manufacturing, quality control, and clear claims management. Firms should also build post-market evidence systems that track performance, antimicrobial reduction outcomes, animal welfare indicators, productivity metrics, and producer return on investment.

Research Methodology

This executive summary is developed using secondary research from recognized public sources, including global One Health guidance, veterinary antimicrobial stewardship frameworks, regulatory agency publications, peer-reviewed scientific literature, animal production databases, and animal health industry reports.

The methodology applies triangulation across regulatory evidence, scientific feasibility, production-system relevance, and commercial adoption indicators. Insights are validated by comparing policy direction, animal production trends, antimicrobial resistance priorities, technology readiness, and regional market conditions. Claims are limited to evidence-supported observations and do not rely on speculative market sizing, market share, or forecasting.

Conclusion and Strategic Outlook

Animal antibacterial peptides are positioned at the intersection of antimicrobial stewardship, precision animal health, and sustainable protein production. Their market relevance is rising as producers and veterinarians seek effective tools that can reduce dependence on conventional antibiotics without compromising animal welfare, productivity, or food safety.

The strongest opportunities will favor organizations that combine peptide science with validated delivery systems, regulatory discipline, AI-enabled discovery, scalable manufacturing, and practical farm-level economics. As resistance concerns and food safety expectations intensify, animal antibacterial peptides can become an important component of integrated disease prevention and responsible animal health management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Animal Antibacterial Peptide Market, by Product Type

• 7.1. Naturally Derived Peptide
• 7.2. Synthetic Peptide
  • 7.2.1. Long Chain
  • 7.2.2. Medium Chain
  • 7.2.3. Short Chain

8. Animal Antibacterial Peptide Market, by Animal Type

• 8.1. Food-Producing Animals
  • 8.1.1. Cattle
  • 8.1.2. Poultry
  • 8.1.3. Swine
• 8.2. Companion Animals
  • 8.2.1. Dogs
  • 8.2.2. Cats

9. Animal Antibacterial Peptide Market, by Mode of Delivery

• 9.1. Oral
• 9.2. Injectable
• 9.3. Topical

10. Animal Antibacterial Peptide Market, by Application

• 10.1. Growth Promotion
• 10.2. Prophylactic
  • 10.2.1. Disease Prevention
  • 10.2.2. Vaccination Adjuvant
• 10.3. Therapeutic
  • 10.3.1. Infection Treatment
  • 10.3.2. Skin Disease Treatment

11. Animal Antibacterial Peptide Market, by End User

• 11.1. Aquaculture Farms
• 11.2. Feed Manufacturers
  • 11.2.1. Aquafeed
  • 11.2.2. Livestock Feed
• 11.3. Research Institutes
  • 11.3.1. Academic Institute
  • 11.3.2. Biotech Company
• 11.4. Veterinary Clinics
  • 11.4.1. Large Animal Practice
  • 11.4.2. Small Animal Practice

12. Animal Antibacterial Peptide Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Animal Antibacterial Peptide Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Animal Antibacterial Peptide Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AB Vista Limited
• 16.2. AgroBioTek Laboratories LLC
• 16.3. Anitox Corporation
• 16.4. Biogenesis Bago S.A.
• 16.5. Biosynth Ltd
• 16.6. Boehringer Ingelheim International GmbH
• 16.7. Cargill, Incorporated
• 16.8. Dechra Pharmaceuticals PLC
• 16.9. Eco Animal Health Ltd.
• 16.10. Elanco Animal Health Incorporated
• 16.11. Esco Aster Pte. Ltd.
• 16.12. Genera Inc.
• 16.13. Huvepharma S.A.
• 16.14. ImmuCell Corporation
• 16.15. Kemin Industries, Inc.
• 16.16. Merck & Co., Inc.
• 16.17. Neogen Corporation
• 16.18. Novozymes A/S
• 16.19. Phibro Animal Health Corporation
• 16.20. Vetbiochem India Pvt Ltd.
• 16.21. Vetoquinol S.A.
• 16.22. Zoetis Inc.
• 16.23. Zomedica Pharmaceuticals Corp.